logo-loader
HealthPharma & Biotech
viewPreveCeutical Medical Inc

PreveCeutical awarded default judgement on civil claim in British Columbia

The health sciences company received a judgement against JCN Capital Corp

judge's gavel
The company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) obtained a default judgement in a Supreme Court of British Columbia civil case, the company announced Monday.

The health sciences company received a default judgement against JCN Capital Corp in connection with a case brought by PreveCeutical alleging fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance.

READ: PreveCeutical gets default judgement in part of civil claim

The Vancouver-based company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements.

"We are pleased to have received this third default judgement as it demonstrates that PreveCeutical is actively pursuing this action," said PreveCeutical Chairman and CEO Stephen Van Deventer in a statement.

The amount of damages and costs awarded to PreveCeutical are still being assessed by the court.

The company continues to pursue other civil cases in the courts, according to a statement.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: PreveCeutical Medical Inc

Price: 0.02 CAD

CSE:PREV
Market: CSE
Market Cap: $7.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19

2 min read